Step by Step

INTRODUCTION

ABIM MOC Activity ID

10/10/2023 - Medical Grand Rounds: Gastrointestinal Medical Oncology Research Year in Review

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

In this session, we will feature an installment of our "Year in Review" Series. This series highlights practice-changing updates in various medical fields, and in this session, we will hear from our experts in the Hematology/Oncology Division. Today's topic is "Gastrointestinal Medical Oncology Research – Year in Review"

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe advances in standard therapeutics and research developments for chemotherapy refractory colorectal cancer
  • Recognize immunotherapy advancements in gastric and esophageal cancer
  • Identify predictors of response to immunotherapy in gastric and esophageal cancer

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Suggested additional Reading:

  • Grothey A, Van Cutsem E, Sobrero A, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12.
  • Kato K, Shah MA, Enzinger PC, Bennouna J, Shen L, Adenis A, et al. Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer. Annals of Oncology. 2018;29:viii268–9.
  • Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398:27–40.
  • Park R, Da Silva LL, Saeed A. Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. Cancers. 2021;13:1715.


Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Authors:
Anwaar Saeed, MD — Associate Professor of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine
Dr. Saeed receives grant/research support from Merck, AstraZeneca, Bristol Myers Squibb, KAHR Medical, Dragonfly Therapeutics, Innovent Biologics, Exelixis, Clovis, Incyte Corporation, Actuate Therapeutics, and Oxford Biotherapeutics. He is a consultant with Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, and Exelixis.
Ibrahim Sahin, MD — Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine
Dr. Sahin receives grant/research support from Bayer and GSK. He is a consultant with Seagen and GSK.
Janie Zhang, MD — Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine
No planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.